If you enjoy this content, please share it with a colleague
RELATED CONTENT
Learn more about myQA, IBA’s unique platform that connects QA applications, people, and know-how through a central ...
This brief video highlights the grassroots effort from IBA Dosimetry to satisfy customers through value added services ...
IBA (Ion Beam Applications S.A.) announced the completion of the divestiture of IBA Molecular North America Inc. (IBAM NA) to Illinois Health and Science (IHS), a non-profit healthcare system.
IBA (Ion Beam Applications S.A.) announced the successful debut of the IBA Dosimetry Support Portal. The most recent addition of the IBA CAREprogram initiative, the Support Portal adds emphasis on customer satisfaction by offering continuous service accessibility and improved service quality for global customer convenience.
Teams at the Willis-Knighton Cancer Center in Shreveport, Louisiana, have achieved high levels of quality care, ease of use and speed of treatment in 11 months on IBA’s Proteus One compact proton therapy system.
IBA (Ion Beam Applications S.A.) announced that the first patient case in the United States has successfully been quality controlled using myQA Global QA Platform at the LewisGale Regional Center in Pulaski, Virginia.
IBA (Ion Beam Applications S.A.) has signed three separate binding term sheets with Proton Partners International (PPI) to install three of its Proteus One compact proton therapy solutions in private clinics in the United Kingdom. The agreements contain significant and immediate down-payments.
IBA (Ion Beam Applications S.A.) and Royal Philips announced the signing of an exclusive agreement to enhance access to proton therapy in India. The alliance combines IBA’s strengths in proton therapy and Philips’ expertise in clinical informatics and innovative imaging techniques for therapy planning and guidance.
IBA (Ion Beam Applications S.A.) announced the successful completion of its fifth IBA Academy on the Road enhanced training workshop. This, and several other training offerings, are key cornerstones of the IBA CAREprogram initiative, which allows close partnering with IBA customers for optimized user satisfaction.
In May, Group of Companies European Medical Center (GEMC) became the first private clinic in Russia to open a positron emission tomography (PET-CT) department producing its own pharmaceuticals. GEMC also opened a radiation cancer therapy department featuring two linear accelerators.